| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MEDP | Common Stock | Purchase | $9.54M | +62.5K | +1.05% | $152.66 | 6.02M | Sep 14, 2022 | By Medpace Investors, LLC | F1, F2, F3 |
| transaction | MEDP | Common Stock | Purchase | $9.57M | +62.5K | +1.04% | $153.11 | 6.08M | Sep 15, 2022 | By Medpace Investors, LLC | F1, F3, F4 |
| holding | MEDP | Common Stock | 807K | Sep 14, 2022 | Direct |
| Id | Content |
|---|---|
| F1 | The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 17, 2022, as amended on May 3, 2022 and August 15, 2022. |
| F2 | The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $149.49 to $155.34. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. |
| F3 | The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| F4 | The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $150.94 to $155.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. |